Vantictumab, formerly known as OMP18R5, represents the novel targeted body designed for specifically block bone associated receptor 18R5. Such therapy is currently developed by Amgen in anticipated uses in various bone diseases, particularly situations involving abnormal bone resorption. Preclinical findings suggest that is able to significantly di